BONESUPPORT, based in Sweden, has obtained the US Food and Drug Administration (FDA) approval to initiate an Investigational Device Exemption (IDE) FORTIFY trial of CERAMENT G.

CERAMENT G is an injectable antibiotic-eluting bone graft substitute, which has been designed to provide local sustained delivery of gentamicin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bonesupport CEO Richard Davies said: "The FDA approval of our planned IDE study with CERAMENT G is a key corporate milestone for BONESUPPORT.

"The results of this study will form a key component of our planned PMA to gain US approval for this novel antibiotic-eluting bone graft substitute."

“We are looking forward to beginning the FORTIFY study before the end of 2016.

“The results of this study will form a key component of our planned PMA to gain US approval for this novel antibiotic-eluting bone graft substitute."

See Also:

The randomised, multicentre and controlled FORTIFY trial intends to determine the safety and efficacy of CERAMENT G as part of surgical repair of open diaphyseal tibial fractures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is slated to commence at the end of this year and should enroll up to 230 patients.

The trial is primarily focused on ascertaining the efficacy of the device in healing infection at the fracture site and eliminating the requirement of surgical or non-surgical procedures to heal a fracture.

CERAMENT G’s drug-eluting properties deliver an initial ultra-high concentration of gentamicin to the bone fracture site to facilitate bone healing and promote bone remodeling.

It then delivers a longer sustainable dose above the minimum inhibitory concentration (MIC) of many of the bacteria which could cause a deep bone infection at the fracture site.